Evogene: EPS übertrifft Schätzungen um 0,19 $

Investing.com – Evogene (NASDAQ: ) has a quarterly EPS report of -$1,060, $0.19 more than an analyst estimate of -$1,250.

The sums for the purchase of four years are worth 914K$, and the final estimates are worth 775K$.

The action of Evogene included the official trade on the Schlussstand of 3.98$. In the last 3 months the performance was minus -51.460%, in the last 12 months it was minus -48.510%.

Evogene has recently published 90 days with 2 positive EPS revisions and 0 negative EPS revisions. These früheren Reaktionen des Aktienkurses von Evogene auf die Vorlage der Geschäftszahlen could be found here.

InvestingPro considers that financing from Evogene from the basic financial knowledge as “durchschnittlich”.

You can find information about Evogene’s information here.

All bilanztermine und -ergebnisse finden Sie in unserem Bilanzkalender, der für eine Vielzahl von Unternehmen in Realtime updated.